These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 26203609)
41. Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD). Ulrik CS Expert Opin Pharmacother; 2015; 16(17):2653-9. PubMed ID: 26641535 [TBL] [Abstract][Full Text] [Related]
42. Recent advances in pharmacotherapy for dyspnea in COPD. Raghavan N; Webb K; Amornputtisathaporn N; O'Donnell DE Curr Opin Pharmacol; 2011 Jun; 11(3):204-10. PubMed ID: 21450522 [TBL] [Abstract][Full Text] [Related]
43. Attitudes of patients with chronic breathlessness towards treatment with opioids. Verberkt CA; van den Beuken-van Everdingen MHJ; Wouters EFM; Janssen DJA Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31699842 [No Abstract] [Full Text] [Related]
44. Three-minute constant rate step test for detecting exertional dyspnea relief after bronchodilation in COPD. Borel B; Wilkinson-Maitland CA; Hamilton A; Bourbeau J; Perrault H; Jensen D; Maltais F Int J Chron Obstruct Pulmon Dis; 2016; 11():2991-3000. PubMed ID: 27942208 [TBL] [Abstract][Full Text] [Related]
45. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)]. Szmidt M Pneumonol Alergol Pol; 2012; 80(3):255-62. PubMed ID: 22562275 [TBL] [Abstract][Full Text] [Related]
46. Excess Ventilation in Chronic Obstructive Pulmonary Disease-Heart Failure Overlap. Implications for Dyspnea and Exercise Intolerance. Rocha A; Arbex FF; Sperandio PA; Souza A; Biazzim L; Mancuso F; Berton DC; Hochhegger B; Alencar MCN; Nery LE; O'Donnell DE; Neder JA Am J Respir Crit Care Med; 2017 Nov; 196(10):1264-1274. PubMed ID: 28665692 [TBL] [Abstract][Full Text] [Related]
47. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Lee TM; Lin MS; Chang NC Am J Cardiol; 2008 Feb; 101(4):530-5. PubMed ID: 18312772 [TBL] [Abstract][Full Text] [Related]
48. Management of refractory breathlessness with morphine in patients with chronic obstructive pulmonary disease. Smallwood N; Le B; Currow D; Irving L; Philip J Intern Med J; 2015 Sep; 45(9):898-904. PubMed ID: 26332621 [TBL] [Abstract][Full Text] [Related]
49. Attitudes toward opioids for refractory dyspnea in COPD among Dutch chest physicians. Janssen DJ; de Hosson SM; bij de Vaate E; Mooren KJ; Baas AA Chron Respir Dis; 2015 May; 12(2):85-92. PubMed ID: 25676931 [TBL] [Abstract][Full Text] [Related]
50. Chronic obstructive pulmonary disease: the evidence for use of tiotropium. Burns G; Bianchi S Br J Hosp Med (Lond); 2006 Feb; 67(2):85-91. PubMed ID: 16498916 [No Abstract] [Full Text] [Related]
51. Acupuncture for dyspnea on exertion in chronic obstructive pulmonary disease: no blindness. Mommaerts JL; Vandevoorde J; Devroey D Arch Intern Med; 2012 Dec; 172(22):1772-3; author reply 1773. PubMed ID: 23229948 [No Abstract] [Full Text] [Related]
52. Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches. Ora J; Jensen D; O'Donnell DE Curr Opin Pulm Med; 2010 Mar; 16(2):144-9. PubMed ID: 19926997 [TBL] [Abstract][Full Text] [Related]
53. Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease. Horton R; Rocker G Curr Opin Support Palliat Care; 2010 Jun; 4(2):56-62. PubMed ID: 20407378 [TBL] [Abstract][Full Text] [Related]